- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
- Interventions
- Placebo, Sotagliflozin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1705–1728
of 1,872
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors
- Interventions
- ABBV-706, Cisplatin, Budigalimab, Carboplatin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Gilbert, Arizona • Duarte, California • Irvine, California + 18 more
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- Hyperbaric Oxygen
- Device
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Colorectal Cancer
- Interventions
- EGEN-001-301
- Drug
- Lead sponsor
- EGEN, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Zion, Illinois
- Conditions
- Familial Partial Lipodystrophy
- Interventions
- volanesorsen, Placebo
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
- Interventions
- Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Type 1 Diabetes
- Interventions
- Aerobic Exercise, Resistance Exercise
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy
- Interventions
- Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
- Interventions
- Sacituzumab govitecan, Adaptive Radiotherapy
- Drug · Radiation
- Lead sponsor
- Shilpa Gupta, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pregnancy Related
- Interventions
- Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Background PAH Therapy
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more
- Conditions
- Major Depressive Disorder
- Interventions
- Ketamine, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Scleritis
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adolescent Alcohol Use
- Interventions
- Brief Motivational Interviewing-based Alcohol Intervention, Smartphone App-delivered Mindfulness Training
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 13
- States / cities
- Baltimore, Maryland • Belcamp, Maryland • Bowie, Maryland + 6 more
- Conditions
- Cancer, Adjustment Disorders
- Interventions
- MDMA
- Drug
- Lead sponsor
- Sunstone Medical
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Rebif Rebidose, Rebiject II
- Device
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 21
- States / cities
- Cullman, Alabama • Tuscon, Arizona • Newport Beach, California + 18 more
- Conditions
- Metastatic Malignant Neoplasm to Brain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Hypofractionated Radiosurgery
- Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Hypertension
- Interventions
- Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Chronic Low-back Pain
- Interventions
- Enhanced Self-Care (ESC), Acceptance and Commitment Therapy (ACT), Evidence-Based Exercise and Manual Therapy (EBEM), Duloxetine
- Behavioral · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Redwood City, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
- Conditions
- Bipolar Disorder
- Interventions
- CARE
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Cranston, Rhode Island • Providence, Rhode Island
- Conditions
- Type 2 Diabetes
- Interventions
- Fresh Food Farmacy
- Other
- Lead sponsor
- John B Bulger, DO
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Lewistown, Pennsylvania • Scranton, Pennsylvania
- Conditions
- Parkinson Disease
- Interventions
- Progressive Resistance Training (PRT), Delayed Exercise Training (DE), Endurance Training (ET)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
- Interventions
- Rituximab, Filgrastim, EPOCH
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland